Scientific References Check out the scientific literature that supports our molecular targets and our synthetic lethal approach. October 2023 Circulating tumor DNA (ctDNA) genomic and epigenomic profiling (GuardantINFINITY) for diagnosis of DNA damage repair (DDR) loss of function (LOF) and response monitoring in the TRESR and ATTACC trials Ezra Rosen, Joseph D. Schonhoft, Et Al. AACR-NCI-EORTC INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS June 2023 Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results Timothy A. Yap, Elisa Fontana, Et Al. Nature Medicine May 2023 Detection of Biallelic Loss of DNA Repair Genes in Formalin-Fixed, Paraffin-Embedded Tumor Samples Using a Novel Tumor-Only Sequencing Panel Dominik Glodzik, Pier Selenica, Et Al. The Journal of Molecular Diagnostics April 2023 Characterization of CCNE1 amplifications and associated genomic features in ovarian and uterine cancers Sunantha Sethuraman, Dominik Glodzik, Et Al. AACR 2023 April 2023 Investigating Wee1 and Myt1 combined inhibition as a potential cancer therapeutic strategy Sargun Sokhi, Joanne Hadfield, Et Al. AACR 2023 April 2023 Tumor heterogeneity of CCNE1 copy number assessed by fluorescence in situ hybridization (FISH) in ovarian and uterine cancers Adam Petrone, Elia Aguado-Fraile, Et Al. AACR 2023 September 2022 Identification of RP-6685, an Orally Bioavailable Compound that Inhibits the DNA Polymerase Activity of Polθ Monica Bubenik, Pavel Mader, Et Al. Journal of Medicinal Chemistry July 2022 Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306 Janek Szychowski, Robert Papp, Et Al. American Chemical Society July 2022 Guiding ATR and PARP inhibitor combinationswith chemogenomic screens Zimmermann M, Bernier C, Et Al. Cell Reports April 2022 CCNE1 amplification is synthetic-lethal with PKMYT1 kinase inhibition Gallo D, Young JTF, Fourtounis J, et al. Nature 12345 We have a number of synthetic lethal therapies in development. View Pipeline
